Cargando…

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

BACKGROUND: Acquired epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance limits the long-term clinical efficacy of tyrosine kinase-targeting drugs. Although most of the mechanisms of acquired EGFR-TKI resistance have been revealed, the mechanism of ~ 15% of cases has not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Yulong, Zhang, Yang, Lei, Zhe, Liu, Ting, Cai, Tingting, Wang, Anqi, Du, Wenwen, Zeng, Yuanyuan, Zhu, Jianjie, Liu, Zeyi, Huang, Jian-an
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720454/ https://www.ncbi.nlm.nih.gov/pubmed/33287873 http://dx.doi.org/10.1186/s13045-020-01009-7

Ejemplares similares

Integrin α3/α6 and αV are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression
por: Zhou, Jieqi, et al.
Publicado: (2022)

The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
por: Du, Wenwen, et al.
Publicado: (2020)

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
por: Lian, Zengzhi, et al.
Publicado: (2020)

CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer
por: Zhu, Jianjie, et al.
Publicado: (2021)

The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
por: Zhang, Yang, et al.
Publicado: (2019)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
por: Wang, Zhi, et al.
Publicado: (2022)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
por: WANG, CHENGDE, et al.
Publicado: (2015)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Arasada, Rajeswara Rao, et al.
Publicado: (2018)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
por: Kauffmann-Guerrero, Diego
Publicado: (2020)

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
por: Han, Ruoshuang, et al.
Publicado: (2021)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

FTO facilitates cancer metastasis by modifying the m(6)A level of FAP to induce integrin/FAK signaling in non-small cell lung cancer
por: Gao, Lirong, et al.
Publicado: (2023)

The regulation of Neuropilin 1 expression by miR‐338‐3p promotes non‐small cell lung cancer via changes in EGFR signaling
por: Ding, Zongli, et al.
Publicado: (2019)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours
por: Yue-Yun, Chen, et al.
Publicado: (2019)

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
por: Hafner, Susanne
Publicado: (2021)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
por: Sun, Li, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer
por: Chen, Junjie, et al.
Publicado: (2023)

An EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast cancer
por: Tai, Yu-Ling, et al.
Publicado: (2015)

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
por: Xu, Qinghua, et al.
Publicado: (2019)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
por: Gkountakos, Anastasios, et al.
Publicado: (2022)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3p2k7jd3k9blmao39kst5ls8ui